Literature DB >> 11090522

Lifestyle medicines.

D Gilbert1, T Walley, B New.   

Abstract

Keywords:  Health Care and Public Health; National Health Service

Mesh：

Substances：

Year:  2000        PMID： 11090522      PMCID： PMC1119073          DOI： 10.1136/bmj.321.7272.1341

Source DB:  PubMed          Journal:  BMJ        ISSN： 0959-8138


× No keyword cloud information.
  15 in total

1.  Is norethisterone a lifestyle drug? Results of database analysis.

Authors:  J Shakespeare; E Neve; K Hodder
Journal:  BMJ       Date:  2000-01-29

2.  Valuing the effects of sildenafil in erectile dysfunction. Strong assumptions are required to generate a QALY value.

Authors:  N Freemantle
Journal:  BMJ       Date:  2000-04-29

3.  Prescription charges: change overdue? Britain can learn from systems of copayments based on drugs' effectiveness.

Authors:  T Walley
Journal:  BMJ       Date:  1998-08-22

4.  Retracing the Oregon trail: the experience of rationing and the Oregon health plan.

Authors:  C Ham
Journal:  BMJ       Date:  1998-06-27

5.  UK issues guidance on prescribing Viagra.

Authors:  L Beecham
Journal:  BMJ       Date:  1999-01-30

6.  The NHS: possibilities for the endgame. Think more about reducing expectations.

Authors:  R Smith
Journal:  BMJ       Date:  1999-01-23

7.  Scenario analysis of the future of medicines.

Authors:  H Leufkens; F Haaijer-Ruskamp; A Bakker; G Dukes
Journal:  BMJ       Date:  1994-10-29

8.  Prescribing for obesity. Comment on the Royal College of Physicians' Working Party report on clinical management of overweight and obese patients with particular reference to drugs.

Authors:  P Kopelman
Journal:  J R Coll Physicians Lond       Date:  1999 Jan-Feb

9.  Why are patients prescribed proton pump inhibitors? Retrospective analysis of link between morbidity and prescribing in the General Practice Research Database.

Authors:  J N Bashford; J Norwood; S R Chapman
Journal:  BMJ       Date:  1998-08-15

10.  Compliance with restrictions on the subsidized use of proton pump inhibitors in Australia.

Authors:  P McManus; J Marley; D J Birkett; J Lindner
Journal:  Br J Clin Pharmacol       Date:  1998-10       Impact factor: 4.335
View more
  11 in total

1.  Selling sickness: the pharmaceutical industry and disease mongering.

Authors:  Ray Moynihan; Iona Heath; David Henry
Journal:  BMJ       Date:  2002-04-13

2.  The use of the terms 'lifestyle medicines' or 'lifestyle drugs'.

Authors:  Claus Møldrup
Journal:  Pharm World Sci       Date:  2004-08

3.  [To improve quality healthcare does not imply publicly funding any drug].

Authors:  Ester Amado Guirado; Laura Diego; Vicente Ortún
Journal:  Aten Primaria       Date:  2012-02-09       Impact factor: 1.137

4.  Therapeutic innovation in the European Union: analysis of the drugs approved by the EMEA between 1995 and 2003.

Authors:  Domenico Motola; Fabrizio De Ponti; Pasqualino Rossi; Nello Martini; Nicola Montanaro
Journal:  Br J Clin Pharmacol       Date:  2005-04       Impact factor: 4.335

5.  Functional foods: the case for closer evaluation.

Authors:  Nynke de Jong; Olaf H Klungel; Hans Verhagen; Marion C J Wolfs; Marga C Ocké; Hubert G M Leufkens
Journal:  BMJ       Date:  2007-05-19

6.  Asymptotic medicine.

Authors:  Karmen Loncarek
Journal:  Croat Med J       Date:  2009-02       Impact factor: 1.351

Review 7.  Lifestyle medicines and the elderly.

Authors:  Tom Walley
Journal:  Drugs Aging       Date:  2002       Impact factor: 3.923

Review 8.  [Lifestyle drugs in medicine].

Authors:  Wolfgang Harth; Kurt Seikowski; Barbara Hermes; Uwe Gieler
Journal:  Wien Med Wochenschr       Date:  2008

9.  Lifestyle drugs: concept and impact on society.

Authors:  S Z Rahman; V Gupta; Anupama Sukhlecha; Y Khunte
Journal:  Indian J Pharm Sci       Date:  2010-07       Impact factor: 0.975

Review 10.  Beyond access to medicines: Eliciting high-income country support for a new global health research and development paradigm.

Authors:  Sadie Regmi; Benjamin Skov Kaas-Hansen; Johanne Helene Iversen
Journal:  J Glob Health       Date:  2013-12       Impact factor: 4.413
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.